The National Human Genome Research Institute (NHGRI) funded a collaborative large-scale genome sequencing effort in 2016 to comprehensively identify rare risk and protective variants contributing to multiple common disease phenotypes. This initiative explores a range of diseases with the goal of:
The CCDGs study cardiovascular diseases (early-onset cardiovascular disease, atrial fibrillation, hemorrhagic stroke), neuropsychiatric diseases (autism, Alzheimer's disease, epilepsy), and immune-mediated diseases (irritable bowel disorder, asthma, Type-1 diabetes). CCDG studies have been limited to the nine selected diseases to increase study power.
The CCDGs collaborate with other projects, including the National Heart Lung and Blood Institute (NHLBI) Trans-omics for Precision Medicine program. The centers also receive co-funding from NHLBI.
We currently estimate that the CCDG program will sequence approximately 100K whole genomes and 125K whole exomes during the life of the program.
More information on the CCDGs, including publications, can be found on the Coordinating Center managed website: http://ccdg.rutgers.edu/.
Funding for the CCDG - awarded January 14, 2016:
Last Updated: September 26, 2018